The Economics of Crisis Innovation Policy: A Historical Perspective

11 Pages Posted: 12 Jan 2021 Last revised: 20 Jul 2021

See all articles by Daniel P. Gross

Daniel P. Gross

Duke University - Fuqua School of Business; National Bureau of Economic Research

Bhaven N. Sampat

Columbia University - Mailman School of Public Health

Multiple version iconThere are 2 versions of this paper

Date Written: January 2021

Abstract

Since the beginning of the COVID-19 pandemic, policymakers, researchers, and journalists have made comparisons to World War II. In 1940, a group of top U.S. science administrators organized a major coordinated research effort to support the Allied war effort, including significant investments in medical research which yielded innovations like mass-produced penicillin, antimalarials, and a flu vaccine. We draw on this episode to discuss the economics of crisis innovation. Since the objectives of crisis R&D are different than ordinary R&D (prioritizing speed, coordination, redundancy, and more), we argue that appropriate R&D policy in a crisis requires going beyond the standard Nelson-Arrow framework for research policy.

Suggested Citation

Gross, Daniel P. and Sampat, Bhaven N., The Economics of Crisis Innovation Policy: A Historical Perspective (January 2021). NBER Working Paper No. w28335, Available at SSRN: https://ssrn.com/abstract=3763864

Daniel P. Gross (Contact Author)

Duke University - Fuqua School of Business ( email )

Box 90120
Durham, NC 27708-0120
United States

National Bureau of Economic Research ( email )

1050 Massachusetts Avenue
Cambridge, MA 02138
United States

Bhaven N. Sampat

Columbia University - Mailman School of Public Health ( email )

600 West 168th St. 6th Floor
New York, NY 10032
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
27
Abstract Views
180
PlumX Metrics